Trump administration will allow pharmacies to make popular peptides

Key Points:

• The Department of Health and Human Services (HHS) announced a new policy allowing small compounding pharmacies to produce six unproven peptides, exercising enforcement discretion despite an official ban and lack of FDA approval.
• Health Secretary Robert F. Kennedy Jr., a supporter of peptides, has endorsed their use, though these substances have limited scientific evidence supporting their safety and effectiveness.
• The policy targets small 503A compounding pharmacies, not larger 503B facilities, meaning production will be limited and likely unable to meet high consumer demand.
• Supporters argue the policy offers a safer, regulated alternative to illicit peptides sold online, while critics—including consumer advocacy groups—warn it undermines FDA authority and poses public health risks by bypassing standard drug approval processes.
• Industry experts caution that it may take time for compounding pharmacies to supply these peptides due to ingredient verification requirements, and some groups have petitioned the FDA to maintain restrictions given ongoing safety concerns.